Compare Citigroup Inc. (C) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs Smith & Nephew plc — how do they compare? Citigroup Inc. trades at $134.33 (market cap $227.30B), while Smith & Nephew plc trades at $31.1 (market cap $12.40B). The key difference: Citigroup Inc. is far larger — about 18.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| C | SNN | |
|---|---|---|
Market Cap | $227.30B | $12.40B |
Sector | Financials | Health |
52-Week High | $145.67 | $38.70 |
52-Week Low | $90.02 | $28.73 |
Dividend Yield | 1.8% | 2.62% |
Enterprise Value | — | $15.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.
The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
